- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Rockwell Medical Inc(RMTI)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RMTI
11/20/2026: RMTI (1-star) is currently NOT-A-BUY. Pass it for now.
Rockwell Medical Inc is a micro-cap healthcare company that supplies essential hemodialysis concentrates and ancillary products to renal care providers. The company's main business strengths include established relationships with leading national dialysis operators and steady year-over-year revenue growth. Its primary investment story centers on organic clinic demand and opportunities to scale operations through strategic asset expansion. However, key risks involve historical net unprofitability, intense competition from vertically integrated healthcare giants, and share price volatility. The stock may best suit tactical or growth-oriented investors willing to monitor execution milestones and quarterly cash flow improvements.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Top-line revenue expansion and potential asset integration offer growth avenues, offset by historical unprofitability. |
| Momentum investor | Strong fit while signal remains positive | The stock is prone to sharp single-session moves on strategic headlines, making it suitable for tactical momentum strategies during upturn signals. |
| Value investor | Weak fit | Micro-cap status, negative net earnings, and volatility make it a challenging fit for traditional value investing. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing instead on business reinvestment. |
| Low-risk investor | Weak fit | Elevated share price volatility and micro-cap risk profile conflict with low-risk investment mandates. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap liquidity and reaction to news create wide swings in share price. |
| Valuation risk | Medium / high | Valuation fluctuates heavily based on market sentiment and execution of forward growth targets. |
| Competition risk (large integrated dialysis providers) | High | The company competes with massive vertically integrated healthcare giants that control their own supply chains. |
| Business quality | Medium | Essential healthcare product demand provides a stable baseline, though net margin consistency requires improvement. |
| Dividend income | Low / none | No dividend is paid to investors. |
| Execution risk | Medium / high | Successfully scaling operations and integrating large transactions is critical for long-term shareholder value. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.12M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 30.0K shares | Beta 1.73 | 52 Weeks Range 4.88 - 12.90 | Updated Date 11/21/2026 |
52 Weeks Range 4.88 - 12.90 | Updated Date 11/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.43 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 75.0%
- Active BUY / eligible
- 9 / 12
- 30-Day BUY Count Change
- +4
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -46.97% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Hemodialysis Concentrates | Sale of liquid and dry acid and bicarbonate concentrates used directly in dialysis treatments. | This is the core engine of the company, generating predictable, recurring revenue from dialysis clinics. |
| Ancillary Dialysis Supplies & Equipment | Sales of cleaning agents, descalers, mixing machines, and specialized kits. | Provides helpful cross-selling opportunities and deepens clinic relationships. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 17.39 | Enterprise Value 15.86M | Price to Sales(TTM) 0.32 |
Enterprise Value 15.86M | Price to Sales(TTM) 0.32 | ||
Enterprise Value to Revenue 0.22 | Enterprise Value to EBITDA 22.09 | Shares Outstanding 3.97M | Shares Floating 3.54M |
Shares Outstanding 3.97M | Shares Floating 3.54M | ||
Percent Insiders 15 | Percent Institutions 7.49 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

